Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma

Clinical Cancer Research

Volumn 12, Issue 22, 2006, Pages 6643-6651

  Perrone, Federica ^a   Suardi, Simona ^a   Pastore, Elisa ^a   Casieri, Paola ^a   Orsenigo, Marta ^a   Caramuta, Stefano ^a   Dagrada, Gianpaolo ^a   Losa, Marco ^a   Licitra, Lisa ^a   Bossi, Paolo ^a   Staurengo, Samantha ^a   Oggionni, Maria ^a   Locati, Laura ^a   Cantu, Giulio ^a   Squadrelli, Massimo ^a   Carbone, Antonino ^a   Pierotti, Marco A ^a,b   Pilotti, Silvana ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; CELL CYCLE PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PROTEIN P16; PROTEIN P16INK4A; PROTEIN P16INK4B; PROTEIN P53; PROTEIN TYROSINE KINASE; VIRUS DNA;

APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CHROMOSOME 7; CONTROLLED STUDY; GENE OVEREXPRESSION; GENETIC ANALYSIS; HEAD AND NECK CARCINOMA; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOLECULAR GENETICS; OROPHARYNX CARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; WART VIRUS; WILD TYPE;

CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYTOGENETIC ANALYSIS; GENES, TUMOR SUPPRESSOR; HUMAN PAPILLOMAVIRUS 16; HUMANS; OROPHARYNGEAL NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 33845297649     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1759     Document Type: Article

References (37)

1. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Nat Cancer Ist 2000;92:709-20.
2. Licitra L, Perrone F, Bossi P, et al. How high-risk human papillomavirus does affect prognosis of patients with oropharyngeal squamous cell carcinoma primarily treated by surgery. J Clin Onc. In press 2006.
3. Slebos RJC, Yi Y, Ely K, et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res 2006;12:701-9.
4. Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Seminars in Oncology 2004;31:744-54.
5. Braakhuis BJM, Snijders PJF, Keune WJH, et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Nat Cancer Ist 2004;96:998-1006.
6. Smeets SJ, Braakhuis BJM, Abbas S, et al. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 2006;25:2558-64.
7. Alsner J, Sørensen SB, Overgaard J. TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. Radiotherapy and Oncology 2001;59:179-85.
8. Temam S, Flahault A, Perie S, et al. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2000;18:385-94.
9. Cabelguenne A, Blons H, deWaziers I, et al. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol 2000;18:1465-73.
10. Poeta LM, Goldwasser MA, Forastiere N, et al. Prognostic implication of p53 mutations in HNSCC: results of intragroup margin study. Abstract 2006 ASCO Annual Meeting Proceedings Part I. Vol. 24, No. 18S, 2006: 5504.
11. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Onc 2006;24:2666-72.
12. Wang-Johanning F, Lu DW, Wang Y, Johnson MR, Johanning GL. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolau tests using real-time polymerase chain reaction analysis. Cancer 2002;94:2199-210.
13. Alkushi A, Lim P, Coldman A, Huntsman D, Miller D, Gilks CB. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Gynec Pathol 2004;23:129-37.
14. INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Clin Cancer Res 2003;9:4132-8.
15. Birindelli S, Perrone F, Oggionni M, et al. Rb and TP53 pathway alterations in sporadic and NF-1 related malignant peripheral nerve sheath tumors. Lab Invest 2001;81:833-44.
16. Loeffler-Ragg J, Witsch-Baumgartner, Tzankov A, et al. Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer 2006;42:109-11.
17. Lee JW, Soung YH, Kim SY, et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 2005;11:2879-82.
18. Lynch TJ, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
19. Frattini M, Ferrario C, Bressan P, et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 2004;23:7436-40.
20. Olshan AF, Weissler MC, Pei H, et al. Alterations of the p16 gene in head and neck cancer: frequency and association with p53, PRAD-1 and HPV. Oncogene 1997;14:811-8.
21. Fakhry C, Gillison ML. Clinical implication of human papillomavirus in head and neck cancers. J Clin Oncol 2006;24:2606-11.
22. Blagosklonny MV. p53: a ubiquitous target of anticancer drugs. Int J Cancer 2002;98:161-6.
23. Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 2005;23:9408-21.
24. Schwartz GK. Development of cell cycle active drugs for the treatment of gastrointestinal cancers: a new approach to cancer therapy. J Clin Onc 2005;23:4499-508.
25. Shah MA, Schwartz GK. Cell cycle mediated drug resistance: an emerging concept in cancer therapy. Clin cancer Res 2005;11:3836-45.
26. Motwani M, Jung C, Sirotnak FM, et al. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in HCT116 colon cancer monolayers and xenografts. Clin Cancer Res 2001;7:4209-19.
27. Carlson B, Lahusen T, Singh S, et al. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol enhances tumor cell apoptosis. Cancer Res 1999;59:4634-41.
28. Kwong RA, Kalish LH, Nguyen TV, et al. p14 protein expression is a predictor of both relapse and survival in squamous cell carcinoma of the anterior tongue. Clin Cancer Res 2005;11:4107-16.
29. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
30. Bishop PC, Myers T, Robey R, et al. Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Oncogene 2002;21:119-27.
31. Cohen EE, Lingen MW, Martin LE, et al. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res 2005;11:8105-8.
32. Mrhalova M, Plzak J, Betka J, Kodet R. Epidermal growth factor receptor - its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas. Neoplasma 2005;52:338-43.
33. Saranath D, Panchal RG, Nair R, Mehta AR, Sanghavi VD, Deo MG. Amplification and overexpression of epidermal growth factor receptor gene in human oropharyngeal cancer. Eur J Cancer B Oral Oncol 1992;2:139-43.
34. Capuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Ist 2005;97:643-55.
35. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:6829-37.
36. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005;6:279-86.
37. Kalish LH, Kwong RA, Cole IE, Gallagher RM, Sutherland RL, Musgrove EA. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2004;10:7764-74.